Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country;Efectos secundarios del tratamiento con benznidazol en una cohorte de pacientes con enfermedad de Chagas en un país no endémico

Revista Espanola de Quimioterapia

Volumn 24, Issue 3, 2011, Pages 123-126

  Carrilero, Bartolomé ^a   Murcia, Laura ^a   Martinez Lage, Laura ^a   Segovia, Manuel ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTHRITIS; ARTICLE; ASTHENIA; BONE MARROW DEPRESSION; CHAGAS DISEASE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DERMATITIS; DIARRHEA; DRUG DOSE INCREASE; FEMALE; FEVER; FOLLOW UP; HAND PARESTHESIA; HEADACHE; HUMAN; INFANT; INFECTION; INSOMNIA; KIDNEY FAILURE; LIMB PAIN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEURITIS; NEUTROPENIA; PRESCHOOL CHILD; SCHOOL CHILD; VERTIGO; VOMITING;

ADULT; ARTHRITIS; CHAGAS DISEASE; COHORT STUDIES; DRUG ERUPTIONS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; NITROIMIDAZOLES; PROSPECTIVE STUDIES; SPAIN; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 80054781996     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. World Health Organization. Reporte del grupo de trabajo científico sobre la enfermedad de Chagas. TDR/GTC/09. Buenos Aires: The Organization; 2005.
2. Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Luquetti A, Travassos LR, et al. Randomized trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996; 348: 1407-1413.
3. Coura JR, Brindeiro PJ, Ferreira I. Benznidazole in the treatment of Chagas disease. Current chemotherapy. Proc 10th Int Cong Chemotherapy 1978; 1: 161-162.
4. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, et al. A Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006; 144: 724-734.
5. Pérez-Molina JA, Pérez-Ayala A, Moreno S, Fernández-González MC, Zamora J, López-Velez R. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. J Antimicrob Chemother 2009; 64: 1139-1147.
6. Viotti R, Vigliano C, Lococo B, Alvarez MG, Petti M, Bertocchi G, et al. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther 2009; 7: 157-163.
7. Murcia L, Carrilero B, Muñoz MJ, Iborra MA, Segovia M. Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas' disease: a prospective study in a non-disease- endemic country. J Antimicrob Chemother 2010; 65:1759-1764.
8. The Medical Letter On Drugs and Therapeutics. Drugs For Parasitic Infections. Mark Abramowicz (Editor). New Rochelle (NY): The Medical Letter 2004.
9. Cancado JR. Long term evaluation of etiological treatment of chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo 2002;44: 29-37.
10. Carpintero DJ. Use of thioctic acid for prevention of the adverse effects induced by benznidazole in patients with chronic Chagas' infection. Medicina (B Aires) 1983; 43: 285-290.
11. Marin-Neto JA, Rassi A Jr, Avezum A Jr, Mattos AC, Rassi A, Morillo CA, et al. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz, Rio de Janeiro 2009, 104: 319-324.
12. Pinazo MJ, Muñoz J, Posada E, López-Chejade P, Gállego M, Ayala E, et al. Tolerance of benznidazole in the treatment of Chagas disease in adults. Antimicrob Agents Chemother 2010;54: 4896-4899.